Ari Nowacek, M.D., Ph.D.

Dr. Nowacek joined ARCH in 2015. He focuses on identifying and evaluating new life sciences technologies and forming companies around them. He was a co-founder of and instrumental in the early development of HiberCell, ROME Therapeutics, and Walden Biosciences. He continues serving all as either a board member/observer or by supporting corporate development. Dr. Nowacek holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital. He holds eight issued patents and applications for therapeutic and R&D applications and has over 25 peer-reviewed publications in the areas of oncology, neuroscience, virology, and antiretroviral therapeutic development.